Silence Therapeutics
SLN
58 hedge funds and large institutions have $106M invested in Silence Therapeutics in 2025 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 15 increasing their positions, 17 reducing their positions, and 10 closing their positions.
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
10% more capital invested
Capital invested by funds: $96.4M → $106M (+$9.64M)
7% more funds holding
Funds holding: 54 → 58 (+4)
12% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 17
27.54% less ownership
Funds ownership: 65.84% → 38.3% (-28%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $278K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$5.17M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.2M |
| 3 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
+$2.34M |
| 4 |
Millennium Management
New York
|
+$2.31M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$10.2M |
| 2 |
Morgan Stanley
New York
|
-$5.65M |
| 3 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$5.03M |
| 4 |
CF
Cantor Fitzgerald
New York
|
-$4.16M |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$639K |
SLN Hedge Fund Activity: Q4 2025 in Review
58 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q4 2025, worth a combined $106M — up 10% from $96.4M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new SLN positions and 10 closed out — a net gain of 4 holders — while 15 added to existing stakes and 17 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $5.17M. The largest seller was Lombard Odier Asset Management (USA), cutting an estimated $10.2M.
- 58 institutional investors held Silence Therapeutics (SLN) as of Q4 2025, up from 54 in Q3 2025.
- Funds reported $106M of Silence Therapeutics stock for Q4 2025, up 10% quarter-over-quarter.
- 14 funds opened new Silence Therapeutics positions in Q4 2025 and 10 closed out, a net change of +4 holders.
- The largest Silence Therapeutics buyer in Q4 2025 was Great Point Partners, an estimated $5.17M added.
- The largest Silence Therapeutics seller in Q4 2025 was Lombard Odier Asset Management (USA), an estimated $10.2M sold.
Based on aggregated 13F filings for Q4 2025.